Shallis RM - Search Results

1

Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence.

Shallis RM, Wang R, Zeidan AM, Huntington SF, Neparidze N, Stempel JM, Mendez LM, Di M, Ma X, Podoltsev NA. Shallis RM, et al. Blood Adv. 2023 Jul 11;7(13):3213-3224. doi: 10.1182/bloodadvances.2022009074. Blood Adv. 2023. PMID: 36939371 Free PMC article.

2

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.

Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. Greenberg PL, et al. Among authors: shallis r. J Natl Compr Canc Netw. 2022 Feb;20(2):106-117. doi: 10.6004/jnccn.2022.0009. J Natl Compr Canc Netw. 2022. PMID: 35130502

3

Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?

Shallis RM, Zeidan AM. Shallis RM, et al. Leuk Lymphoma. 2018 Sep;59(9):2015-2017. doi: 10.1080/10428194.2018.1430797. Epub 2018 Feb 7. Leuk Lymphoma. 2018. PMID: 29411698 No abstract available.

4

More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.

Shallis RM, Zeidan AM. Shallis RM, et al. BMC Hematol. 2018 Feb 1;18:4. doi: 10.1186/s12878-018-0095-2. eCollection 2018. BMC Hematol. 2018. PMID: 29435332 Free PMC article.

5

The genetic and molecular pathogenesis of myelodysplastic syndromes.

Shallis RM, Ahmad R, Zeidan AM. Shallis RM, et al. Eur J Haematol. 2018 Sep;101(3):260-271. doi: 10.1111/ejh.13092. Epub 2018 Jul 12. Eur J Haematol. 2018. PMID: 29742289 Review.

6

Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.

Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Shallis RM, et al. Expert Rev Hematol. 2018 Sep;11(9):715-726. doi: 10.1080/17474086.2018.1503049. Epub 2018 Aug 22. Expert Rev Hematol. 2018. PMID: 30024293 Review.

7

Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts.

Shallis RM, Ahmad R, Zeidan AM. Shallis RM, et al. Eur J Haematol. 2018 Dec;101(6):711-720. doi: 10.1111/ejh.13153. Epub 2018 Oct 10. Eur J Haematol. 2018. PMID: 30055055 Review.

8

Conviction in the face of affliction: a case series of Jehovah's Witnesses with myeloid malignancies.

Shallis RM, Xu ML, Curtis SA, Medoff E, Mixon R, Folkers A, Zeidan AM. Shallis RM, et al. Ann Hematol. 2018 Nov;97(11):2245-2248. doi: 10.1007/s00277-018-3459-6. Epub 2018 Aug 7. Ann Hematol. 2018. PMID: 30088044 Review. No abstract available.

9

Be careful of the masquerades: differentiating secondary myelodysplasia from myelodysplastic syndromes in clinical practice.

Shallis RM, Xu ML, Podoltsev NA, Curtis SA, Considine BT, Khanna SR, Siddon AJ, Zeidan AM. Shallis RM, et al. Ann Hematol. 2018 Dec;97(12):2333-2343. doi: 10.1007/s00277-018-3474-7. Epub 2018 Aug 14. Ann Hematol. 2018. PMID: 30109425

10

Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it.

Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Zeidan AM, et al. Among authors: shallis rm. Blood Rev. 2019 Mar;34:1-15. doi: 10.1016/j.blre.2018.09.001. Epub 2018 Sep 21. Blood Rev. 2019. PMID: 30314642 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

103 results

Search Page

Filters